These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39073577)

  • 1. The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: a post-hoc analysis of the HARUKA phase 3 study.
    Tanaka Y; Takahashi T; van Hoogstraten H; Kato N; Kameda H
    Mod Rheumatol; 2024 Jul; ():. PubMed ID: 39073577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
    Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
    Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI).
    Tanaka Y; Takahashi T; van Hoogstraten H; Kato N; Kameda H
    Mod Rheumatol; 2024 Jul; 34(4):670-677. PubMed ID: 37606691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post-hoc analysis of Japanese phase 3 clinical trials.
    Tanaka Y; Takahashi T; van Hoogstraten H; Kato N; Kameda H
    Mod Rheumatol; 2024 Jul; ():. PubMed ID: 39073574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR
    Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
    Genovese MC; Burmester GR; Hagino O; Thangavelu K; Iglesias-Rodriguez M; John GS; González-Gay MA; Mandrup-Poulsen T; Fleischmann R
    Arthritis Res Ther; 2020 Sep; 22(1):206. PubMed ID: 32907617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials.
    Tanaka Y; Takahashi T; Sumi M; Hagino O; Van Hoogstraten H; Xu C; Kato N; Kameda H
    Mod Rheumatol; 2022 Jul; 32(4):686-695. PubMed ID: 34915576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
    Rubbert-Roth A; Furst DE; Fiore S; Praestgaard A; Bykerk V; Bingham CO; Charles-Schoeman C; Burmester G
    Arthritis Res Ther; 2022 Aug; 24(1):207. PubMed ID: 36008838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
    Burmester GR; Bykerk VP; Buch MH; Tanaka Y; Kameda H; Praestgaard A; van Hoogstraten H; Fernandez-Nebro A; Huizinga T
    Rheumatology (Oxford); 2022 May; 61(6):2596-2602. PubMed ID: 34508594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
    Strand V; Reaney M; Chen CI; Proudfoot CW; Guillonneau S; Bauer D; Mangan E; Graham NM; van Hoogstraten H; Lin Y; Pacheco-Tena C; Fleischmann R
    RMD Open; 2017; 3(1):e000416. PubMed ID: 28326189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.
    Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; van Hoogstraten H; Mangan E; Carita P; Huynh TM
    Adv Ther; 2019 Apr; 36(4):817-827. PubMed ID: 30864105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study.
    Mueller RB; Graninger W; Sidiropoulos P; Goger C; von Kempis J
    Clin Rheumatol; 2017 Oct; 36(10):2187-2192. PubMed ID: 28776300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
    Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
    Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
    Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
    Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
    RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatoid arthritis: previously untreated early disease.
    Gunasekera WM; Kirwan JR
    BMJ Clin Evid; 2016 Aug; 2016():. PubMed ID: 27479367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.